Welcome to our dedicated page for The Valens Company news (Ticker: VLNS), a resource for investors and traders seeking the latest updates and insights on The Valens Company stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect The Valens Company's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of The Valens Company's position in the market.
The Valens Company has entered into two strategic agreements with PMI Mexico to expand its international reach. The first agreement involves supplying CBD for PMI's clinical trials focused on anti-inflammatory applications, with shipments expected in Q1 2022. The second agreement allows Valens to manufacture and distribute Predilife products globally, enhancing its revenue potential through diversified product offerings. This partnership is expected to diversify Valens’ global strategy, providing access to several international markets.
The Valens Company (TSX: VLNS) has secured a non-revolving term loan of up to CAD$40 million with a private lender, which will accrue interest at 10% per annum. This loan aims to fortify its balance sheet, enabling expansion in Canada and the United States. The funds will also be used to retire $7.5 million of existing debt. Valens' leadership emphasized the non-dilutive nature of this financing, which provides financial flexibility and supports the company's aggressive growth trajectory.
The Valens Company has announced the commencement of its common shares trading on the Nasdaq Capital Market under the ticker VLNS as of December 9, 2021. This listing is seen as a significant milestone for the company, enhancing shareholder access to liquidity and corporate visibility. CEO Tyler Robson emphasized that this move supports Valens' global growth initiatives amid the cannabis legalization trend. The company, which provides a variety of cannabis products, continues to focus on product innovation and expansion in key markets, including the U.S. and Australia.
The Valens Company announced approval for its common shares to trade on the Nasdaq Capital Market under ticker symbol VLNS, starting December 9, 2021. This milestone highlights their commitment to expand globally in the cannabis industry. The shares will remain listed on the Toronto Stock Exchange (TSX) and continue trading on OTCQX until the Nasdaq listing begins. CEO Tyler Robson emphasized that this move is key to improving liquidity and enhancing corporate visibility for shareholders.